Abstract Number: 548 • 2018 ACR/ARHP Annual Meeting
Persistence in Low Disease Activity or Remission with Etanercept Monotherapy in Patients with Rheumatoid Arthritis: Results from the Corrona Registry
Background/Purpose: Monotherapy with etanercept (ETN) may be a viable therapeutic option for maintenance of patients with rheumatoid arthritis (RA) who prefer to eliminate potential burdens…Abstract Number: 549 • 2018 ACR/ARHP Annual Meeting
Unmet Treat-to-Target Goals with Available Targeted Immunomodulators in the Management of Rheumatoid Arthritis: Real World Evidence from the Corrona Registry
Background/Purpose: Targeted immunomodulators (TIMs) have revolutionized the therapy of RA and made low disease activity (LDA) a realistic goal for patients. Given the multiple therapy…Abstract Number: 562 • 2018 ACR/ARHP Annual Meeting
Low Inflammation on Magnetic Resonance Imaging in Patients with Rheumatoid Arthritis That Achieved Sustained Clinical Remission on Adalimumab
Background/Purpose: ACR and EULAR recommend bDMARD tapering in patients (pts) with rheumatoid arthritis (RA) who achieved stable clinical remission. Yet, there are limited systematically collected…Abstract Number: 584 • 2018 ACR/ARHP Annual Meeting
Changes in CD4+ T and B Cell Profile As Indicator of Clinical Remission to TNF Inhibitors in Patients with Rheumatoid Arthritis
Background/Purpose: TNF inhibitors (TNFi) are widely used for the treatment of rheumatoid arthritis (RA). This study aims to analyse the profile of peripheral blood mononuclear…Abstract Number: 590 • 2018 ACR/ARHP Annual Meeting
Advances in Therapeutic Management with First Biological Therapy in Rheumatoid Arthritis throughout 15 Years
Background/Purpose: In the last two decades the treatment in patients with rheumatoid arthritis (RA) has undergone major advances, especially due to the appearance of new…Abstract Number: 614 • 2018 ACR/ARHP Annual Meeting
Disease Activity One Year after Addition of Bucillamine or Sulfasaladine to Methotrexate in Japanese Patients with Rheumatoid Arthritis : Propensity Score Analysis
Background/Purpose: Bucillamine (BUC) is a small-molecule disease-modifying antirheumatic drug (DMARD) developed in Japan. The efficacy of combination therapy with BUC and methotrexate (MTX) has been demonstrated…Abstract Number: 867 • 2018 ACR/ARHP Annual Meeting
An MRI Guided Treat-to-Target Strategy in Rheumatoid Arthritis Patients in Clinical Remission Improved MRI Inflammation but Not Damage Progression – Results from the Imagine-RA Randomized Controlled Trial
Background/Purpose: Magnetic Resonance Imaging (MRI) bone marrow edema (BME)/osteitis and MRI synovitis have been identified as predictors of structural damage progression in rheumatoid arthritis RA1,2.…Abstract Number: 881 • 2018 ACR/ARHP Annual Meeting
Association of Comorbidities with DAS28 Disease Status and Remission in Race/Ethnic Groups with Rheumatoid Arthritis
Background/Purpose: Racial/ethnic disparities in comorbidity (CM) in rheumatoid arthritis (RA) may confound treatment and outcomes. Rheumatic Disease Comorbidity Index (RDCI) is a validated tool predicting…Abstract Number: 1451 • 2018 ACR/ARHP Annual Meeting
The Value of Adding MRI to a Clinical Treat-to-Target Strategy in Rheumatoid Arthritis Patients in Clinical Remission: Clinical and Radiographic Outcomes from the Imagine-RA Randomized Controlled Trial
Background/Purpose: Targeting MRI remission in rheumatoid arthritis (RA) patients in clinical remission may improve clinical outcome and halt joint damage progression. The purpose of the…Abstract Number: 1518 • 2018 ACR/ARHP Annual Meeting
Baricitinib and Tofacitinib in Real Life – Does Obesity Impact Response to Janus Kinase Inhibitor Therapy in Rheumatoid Arthritis?
Background/Purpose: The influence of obesity on treatment response of tumor necrosis factor inhibitors in patients with rheumatoid arthritis (RA) is described in literature, but data…Abstract Number: 2468 • 2018 ACR/ARHP Annual Meeting
Window or No Window? Earlier Is Better When Treating Rheumatoid Arthritis
Background/Purpose: Previous reports on a window of opportunity (WOO) in rheumatoid arthritis (RA) may be related to the use of slow acting csDMARDs. We investigated…Abstract Number: 2953 • 2018 ACR/ARHP Annual Meeting
Disappearance of Autoantibodies in RA: Does It Occur with Current Treatment Strategies? a Long-Term Follow-up Study in Patients That Achieved DMARD-Free Sustained Remission
Background/Purpose: Disease modifying antirheumatic drug (DMARD)-free sustained remission, the sustained absence of arthritis after cessation of all DMARD-therapy, is increasingly achievable with current treatment strategies.…Abstract Number: 1449 • 2017 ACR/ARHP Annual Meeting
Development of a Predictive Score of Successful TNF Inhibitor Tapering in Patients with Rheumatoid Arthritis Remission
Background/Purpose: Tapering trials confirmed the feasibility of TNF inhibitors (TNFi) tapering for a relevant proportion of patients in remission and/or low disease activity. However, there…Abstract Number: 1460 • 2017 ACR/ARHP Annual Meeting
Predictive Factors Associated with Successful Down-Titration of Biologics for Rheumatoid Arthritis Patients in Clinical Practice
Background/Purpose: Randomized clinical trials have shown that if a patient is in sustained remission, biological disease-modifying anti rheumatic drugs (bDMARDs) therapy can be tapered in…Abstract Number: 1797 • 2017 ACR/ARHP Annual Meeting
Insights from Treating to Target in Rheumatoid Arthritis at an Academic Medical Center
Background/Purpose: Current RA guidelines recommend treating to a target of remission or low disease activity (RM/LDA) state. In a prior quality improvement (QI) project, our…
- 1
- 2
- 3
- …
- 8
- Next Page »